Investment objective

To provide long-term capital growth by investing primarily in equity securities of U.S. companies whose businesses relate to life sciences and technology and are expected to benefit from scientific and technological advances.

  • Fund Category U.S. Equity Funds
  • Inception Date Aug 13, 2001
Download fund details    Download fund commentary   

Fund details

Series

Currency

Fund code

MER * (%)
F CAD 35070 0.94%

Portfolio analysis As of Mar 31, 2026

99% 1%
Equity Fixed Income

Asset mix

Equity Sector Allocation

Information Technology58.4%
Health Care19.3%
Communication Services19.2%
Industrials1.1%
Consumer Discretionary0.8%
Financials0.8%
Real Estate0.5%

Top 10 Holdings

% Assets
Alphabet Inc - Class A Shares 10.8%
NVIDIA Corp 10.4%
Apple Inc 9.4%
Microsoft Corp 8.0%
Broadcom Inc 4.8%
Meta Platforms Inc - Class A Shares 4.7%
Eli Lilly & Co 2.6%
Johnson & Johnson 2.4%
Netflix Inc 1.7%
Applied Materials Inc 1.4%
Total % of Top 10 Holdings 56.2%

Geographic allocation

Region

Performance analysis

Growth of $10,000 since inception

Calendar returns

Trailing return

Empty column 1 Mth 3 Mth 6 Mth 1 year 3 years 5 years 10 years Since Inception Empty column
10.9 4.1 0.2 36.2 25.9 16.8 19.8 8.9 Fund

Distribution ($)/unit

Empty column YTD* 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Total distributions --- --- --- --- --- --- --- --- --- --- ---
Interest --- --- --- --- --- --- --- --- --- --- ---
Canadian dividends --- --- --- --- --- --- --- --- --- --- ---
Foreign dividends --- --- --- --- --- --- --- --- --- --- ---
Foreign taxes paid --- --- --- --- --- --- --- --- --- --- ---
Capital gains --- --- --- --- --- --- --- --- --- --- ---
Return of capital --- --- --- --- --- --- --- --- --- --- ---

* MER (%) is based on actual expenses for the preceding calendar year or most recent half-year period ended June 30 expressed on an annualized basis, depending on availability of date at the time of publication.